PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Camizestrant→

Camizestrant PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2222844-89-3
Molecular formula
C24H28F4N6
Molecular weight
476.5 g/mol
Drug class
Selective estrogen receptor degrader (SERD)oral endocrine antineoplastic
Mechanism of action
Binds to the oestrogen receptor and promotes receptor degradation, reducing oestrogen-receptor signalling in hormone-receptor-positive breast cancer cells.
Indications / reported uses
  • In combination with abemaciclib, palbociclib or ribociclib for adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer after detection of an ESR1 mutation during first-line aromatase-inhibitor plus CDK4/6-inhibitor therapy, without disease progression; the authorisation is under accelerated/conditional approval frameworks and requires current product-label confirmation

Sources: US FDA — Accelerated approval of camizestrant (4 Sep 2026) · EMA EPAR — Etcamah · NCI Drug Dictionary — Camizestrant · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Camizestrant PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Camizestrant Permitted Daily Exposure (PDE) report (the Camizestrant PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Camizestrant Occupational Exposure Limit (OEL) report (the Camizestrant OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.